CSL Seqirus Signs Agreement to Localize Influenza Vaccine Manufacturing in Saudi Arabia
CSL Seqirus, a subsidiary of CSL Limited, has signed a Memorandum of Understanding with the Ministry of Health of Saudi Arabia to localize the manufacturing of cell-based seasonal and pandemic influenza vaccines. The agreement includes collaboration with Vaccine Industrial Company to produce vaccines at a new facility in Sudair City, expected to start operations in 2028. It also covers the establishment of pre-pandemic vaccine stockpiles and an Advance Purchase Agreement for pandemic vaccines.
CSL Limited announced that its subsidiary, CSL Seqirus, and Vaccine Industrial Company have signed a Memorandum of Understanding with the Ministry of Health of Saudi Arabia to localize the manufacturing of cell-based seasonal and pandemic influenza vaccines in Saudi Arabia. Under the finalized agreement, CSL Seqirus will provide its cell-based influenza vaccines and collaborate with Vaccine Industrial Company to localize production at the new Sudair City facility. The agreement also includes provisions for establishing pre-pandemic vaccine stockpiles and an Advance Purchase Agreement to secure pandemic vaccines for the broader population. The local manufacturing facility is expected to begin operations from 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSL Limited published the original content used to generate this news brief on October 29, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
